Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition
Pharmaceutics · 16.10.2023 · 15 (10) · 2473
DOI: 10.3390/pharmaceutics15102473 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 16.10.2023. Verfasst von Md Masud Parvez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative, Translational & ADME Sciences (QTAS), AbbVie Biotherapeutics, San Francisco, CA 94080, USA. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Biotherapeutics.
Abstract (Originalsprache)
Uptake drug transporters play a significant role in the pharmacokinetic of drugs within the brain, facilitating their entry into the central nervous system (CNS). Understanding brain drug disposition is always challenging, especially with respect to preclinical to clinical translation. These transporters are members of the solute carrier (SLC) superfamily, which includes organic anion transporter polypeptides (OATPs), organic anion transporters (OATs), organic cation transporters (OCTs), and amino acid transporters. In this systematic review, we provide an overview of the current knowledge of uptake drug transporters in the brain and their contribution to drug disposition. Here, we also assemble currently available proteomics-based expression levels of uptake transporters in the human brain and their application in translational drug development. Proteomics data suggest that in association with efflux transporters, uptake drug transporters present at the BBB play a significant role in brain drug disposition. It is noteworthy that a significant level of species differences in uptake drug transporters activity exists, and this may contribute toward a disconnect in inter-species scaling. Taken together, uptake drug transporters at the BBB could play a significant role in pharmacokinetics (PK) and pharmacodynamics (PD). Continuous research is crucial for advancing our understanding of active uptake across the BBB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Quantitative, Translational & ADME Sciences (QTAS), AbbVie Biotherapeutics, San Francisco, CA 94080, USA.
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, 1300 S Coulter St., Amarillo, TX 79106, USA.
- Center for Blood-Brain Barrier Research, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
ORCID-Profile: Md Masud Parvez, Armin Sadighi, Yeseul Ahn, Julius O Enoru
Förderung
- AbbVie Biotherapeutics
Zitieren
APA
Parvez, M. M., Sadighi, A., Ahn, Y., Keller, S. F., & Enoru, J. O. (2023). Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition. Pharmaceutics, 15(10), 2473. https://doi.org/10.3390/pharmaceutics15102473
Vancouver
Parvez MM, Sadighi A, Ahn Y, Keller SF, Enoru JO. Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition. Pharmaceutics. 2023;15(10):2473. doi:10.3390/pharmaceutics15102473
BibTeX
@article{Parvez2023,
author = {Parvez, Md Masud and Sadighi, Armin and Ahn, Yeseul and Keller, Steve F and Enoru, Julius O},
title = {Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {10},
pages = {2473},
doi = {10.3390/pharmaceutics15102473}
}
EUVIMED